Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor

M. Tonini, S. Vigneri, V. Savarino, C. Scarpignato

Research output: Contribution to journalArticle

Abstract

Awareness of important differences in the pharmacological profile of individual optical isomers of chiral drugs led to the development of esomeprazole, the S-isomer of omeprazole, a new pharmacological entity designed to improve the clinical outcome of available proton pump inhibitors in the management of acid-related disorders. The superior acid control achieved by esomeprazole is mainly due to an advantageous metabolism compared with racemate omeprazole, leading to improved bioavailability and to enhanced delivery of the drug to the gastric proton pump.

Original languageEnglish
Pages (from-to)600-606
Number of pages7
JournalDigestive and Liver Disease
Volume33
Issue number7
Publication statusPublished - 2001

Keywords

  • Acid-related disorders
  • Clinical pharmacology
  • Esomeprazole
  • Proton pump inhibitors

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor'. Together they form a unique fingerprint.

  • Cite this